TY - JOUR
T1 - The Role of K-Ras and P53 in Biliary Tract Carcinoma
AU - Ahmad, Saara
AU - Badr, Bisma
AU - Khan, Asra
AU - Rehman, Rehana
AU - Ghias, Kulsoom
AU - Muhammad, Jibran Sualeh
AU - Khan, Muhammad Rizwan
N1 - Publisher Copyright:
© 2021 Pakistan Medical Association. All rights reserved.
PY - 2021/10
Y1 - 2021/10
N2 - Objective: To focus mainly on the role of proto-oncogene Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (K-Ras) and tumour-suppressor gene p53 which are among the most commonly mutated genes in biliary tract carcinomas. Methods: The systematic review comprised research articles published between 2002 and 2019 on PubMed and Google Scholar databases which were searched using the terms TP53 , K-Ras , mutation , biliary tract carcinoma , cholangiocarcinoma , and murine model . Repetitions, duplicates and irrelevant articles were excluded. No data was retrieved from posters, presentations and symposiums, and experiments involving bile aspirations were also excluded. Results: Of the 72 articles reviewed, 11(15.3%) were included. Of them, 3(27.3%) studies, conducted in China, Japan and Taiwan, reported a positive correlation between K-Ras mutation and biliary tract carcinoma. Only 1(9%) study, conducted in China, showed the sole correlation between p53 inactivation and biliary tract carcinoma. Also, 4(36.4%) studies, conducted in China, Japan and Europe, showed a positive association of both K-Ras mutation and p53 inactivation with biliary tract carcinoma. Conclusion:K-Ras and p53 mutation both contribute to biliary tract carcinoma. K-Ras mutation, however, has a much higher frequency compared to p53 inactivation in such cancers.
AB - Objective: To focus mainly on the role of proto-oncogene Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (K-Ras) and tumour-suppressor gene p53 which are among the most commonly mutated genes in biliary tract carcinomas. Methods: The systematic review comprised research articles published between 2002 and 2019 on PubMed and Google Scholar databases which were searched using the terms TP53 , K-Ras , mutation , biliary tract carcinoma , cholangiocarcinoma , and murine model . Repetitions, duplicates and irrelevant articles were excluded. No data was retrieved from posters, presentations and symposiums, and experiments involving bile aspirations were also excluded. Results: Of the 72 articles reviewed, 11(15.3%) were included. Of them, 3(27.3%) studies, conducted in China, Japan and Taiwan, reported a positive correlation between K-Ras mutation and biliary tract carcinoma. Only 1(9%) study, conducted in China, showed the sole correlation between p53 inactivation and biliary tract carcinoma. Also, 4(36.4%) studies, conducted in China, Japan and Europe, showed a positive association of both K-Ras mutation and p53 inactivation with biliary tract carcinoma. Conclusion:K-Ras and p53 mutation both contribute to biliary tract carcinoma. K-Ras mutation, however, has a much higher frequency compared to p53 inactivation in such cancers.
KW - Biliary tract carcinoma
KW - Cholangiocarcinoma
KW - K-Ras
KW - Murine models. (JPMA 71: 2378; 2021)
KW - Mutation
KW - P53
UR - http://www.scopus.com/inward/record.url?scp=85115270938&partnerID=8YFLogxK
U2 - 10.47391/JPMA.11-1322
DO - 10.47391/JPMA.11-1322
M3 - Review article
AN - SCOPUS:85115270938
SN - 0030-9982
VL - 71
SP - 2378
EP - 2384
JO - Journal of the Pakistan Medical Association
JF - Journal of the Pakistan Medical Association
IS - 10
ER -